Search
Eptotermin alfa
go.drugbank.com/drugs/DB11631ApprovedWithdrawnEptotermin alfa is an ingredient in the EMA-withdrawn product Osigraft.
ONO-2952
go.drugbank.com/drugs/DB14802InvestigationalONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
P-113D
go.drugbank.com/drugs/DB04987ExperimentalP-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva. It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.
Synonyms: D-PEPTIDE OF THE SEQUENCE AKRHHGYKRKFH - NH2Indocyanine green acid form
go.drugbank.com/drugs/DB09374ApprovedInvestigationalThe chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide,
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalThe cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.
Products: FASTURTEC 1,5 MG/1 ML INFIZYONLUK COZELTI ICIN TOZ VE COZUCU, 1 ADET, FASTURTEC 7,5 MG/5 ML INFIZYONLUK COZELTI ICIN TOZ VE COZUCU, 1ADETBemegride
go.drugbank.com/drugs/DB13740ExperimentalBemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Nequinate
go.drugbank.com/drugs/DB11433ExperimentalVet approvedNequinate belongs to the family of Hydroquinolones. These are compounds containing an hydrogenated quinoline bearing a ketone group.
Pegilodecakin
go.drugbank.com/drugs/DB15162InvestigationalPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small
Lulizumab pegol
go.drugbank.com/drugs/DB15441InvestigationalLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).